Assignee
SELECTA BIOSCIENCES INC
US·20 granted patents·55 pending applications·333 citations·filing 2010–2023
Top patents by PatentIndex Score
75 records- 0197US11298342B2Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivitySELECTA BIOSCIENCES INC·Filed 2019·Granted Apr 12, 2022·7 cites·20 claims
- 0297US10668053B2Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigenSELECTA BIOSCIENCES INC·Filed 2014·Granted Jun 2, 2020·13 cites·16 claims
- 0397US10046064B2Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Aug 14, 2018·21 cites·13 claims
- 0497US9993548B2Tolerogenic synthetic nanocarriers for inducing regulatory B cellsSELECTA BIOSCIENCES INC·Filed 2014·Granted Jun 12, 2018·30 cites·17 claims
- 0596US10441651B2Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cellsSELECTA BIOSCIENCES INC·Filed 2015·Granted Oct 15, 2019·16 cites·15 claims
- 0696US10420835B2Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cellsSELECTA BIOSCIENCES INC·Filed 2015·Granted Sep 24, 2019·17 cites·19 claims
- 0796US10071114B2Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Sep 11, 2018·20 cites·14 claims
- 0896US10039822B2Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Aug 7, 2018·31 cites·24 claims
- 0996US9764031B2Dose selection of adjuvanted synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2015·Granted Sep 19, 2017·35 cites·18 claims
- 1095US11235057B2Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2018·Granted Feb 1, 2022·8 cites·17 claims
- 1195US10434088B2Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective doseSELECTA BIOSCIENCES INC·Filed 2014·Granted Oct 8, 2019·15 cites·22 claims
- 1295US10357483B2Methods comprising dosing combinations for reducing undesired humoral immune responsesSELECTA BIOSCIENCES INC·Filed 2014·Granted Jul 23, 2019·14 cites·20 claims
- 1395US10357482B2Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivitySELECTA BIOSCIENCES INC·Filed 2014·Granted Jul 23, 2019·16 cites·20 claims
- 1495US10335395B2Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2014·Granted Jul 2, 2019·14 cites·20 claims
- 1595US9884112B2Immunomodulatory agent-polymeric compoundsSELECTA BIOSCIENCES INC·Filed 2015·Granted Feb 6, 2018·22 cites·36 claims
- 1695US9006254B2Immunomodulatory agent-polymeric compoundsSELECTA BIOSCIENCES INC·Filed 2013·Granted Apr 14, 2015·33 cites·27 claims
- 1794US11633422B2Methods and compositions for attenuating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Apr 25, 2023·6 cites·12 claims
- 1894US11426451B2Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressantSELECTA BIOSCIENCES INC·Filed 2018·Granted Aug 30, 2022·7 cites·12 claims
- 1993US11779641B2Tolerogenic synthetic nanocarriers for allergy therapySELECTA BIOSCIENCES INC·Filed 2016·Granted Oct 10, 2023·3 cites·18 claims
- 2092US11717569B2Tolerogenic synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2016·Granted Aug 8, 2023·5 cites·19 claims
- 2190US2024350462A1Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2290US2024261396A1Tolerogenic synthetic nanocarriers for allergy therapySELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2388US2023321225A1Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteinsSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2487US2023321224A1Tolerogenic synthetic nanocarriers to reduce antibody responsesSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2587US2023310593A1Tolerogenic synthetic nanocarriers for allergy therapySELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2686US2024156955A1Tolerogenic synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2785US2023364124A1Methods and compositions for attenuating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2881US2020101155A1Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cellsSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 2981US2020101154A1Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cellsSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3079US2020113874A1Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective doseSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3179US2022354947A1Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3279US2022071968A1Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3377US2023107561A1Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressantSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3473US2020069660A1Methods comprising dosing combinations for reducing undesired humoral immune responsesSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3573US2020069659A1Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3670US2020390881A1Nanocarriers possessing components with different rates of releaseSELECTA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3767US2023139671A1Osmotic mediated release synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3866US2024148841A1Compositions and methods related to immunoglobulin proteases and fusions thereofSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3966US2024024517A1Viral vector dosing protocolsSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4065US2023372535A1Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agentsSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4164US2018256709A1Immunomodulatory agent-polymeric compoundsSELECTA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4264US2023263906A1High affinity il-2 receptor agonists and synthetic nanocarrier dose sparingSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4364US2019076458A1Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4463US2023322884A1Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosingSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4563US2023140196A1Viral vector dosing protocolsSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4663US2023357437A1Immunosuppressants in combination with anti-igm agents and related dosingSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4763US2014242173A1Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agentsSELECTA BIOSCIENCES INC·Filed 2014·Application pending·0 cites
- 4863US2023381277A1High affinity il-2 receptor agonists and immunosuppressants to enhance immune toleranceSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4962US2014030344A1Targeted synthetic nanocarriers with ph sensitive release of immunostimulatory agentsSELECTA BIOSCIENCES INC·Filed 2013·Application pending·0 cites
- 5061US2023141563A1Methods and compositions for attenuating anti-viral transfer vector igm responsesSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →